Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Lymphoid 1

Conditions

Neoplasms 1

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × omipalisib × Tumor-Agnostic × Clear all
NCT01248858 2017-05-09

Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.

GlaxoSmithKline

Phase 1 Terminated
69 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡